To: Pelage Pharmaceuticals, Inc.

Background:

Hair loss, particularly androgenetic alopecia, is a significant burden for millions of people worldwide. The need for effective and safe treatment options is immense. The compound PP405 has shown promising results in preclinical and early clinical studies, holding the potential to become an important new therapeutic option.

Our Request:

As the development of PP405 progresses, the crucial Phase 3 trials are anticipated for 2026. These studies are vital to confirm the efficacy and safety of the compound in a larger patient group and to lay the groundwork for potential regulatory approval.

We, the undersigned of this petition, strongly appeal to Pelage Pharmaceuticals, Inc. to consider Germany as one of the sites for the planned PP405 Phase 3 trials in 2026.

Reasons for Including Germany:

Excellent Research Infrastructure: Germany boasts an excellent and state-of-the-art research infrastructure with numerous renowned university hospitals, research institutes, and specialized dermatological centers, all highly suitable for conducting large-scale clinical trials.
Qualified Medical Professionals: The high quality of medical education and the expertise of healthcare professionals in Germany ensure a professional and meticulous execution of studies according to international standards.
Access to a Broad and Diverse Patient Population: Germany offers a large and heterogeneous patient group that is representative of the European population. This would strengthen the validity of the study results and minimize potential biases.
Accelerated Access for European Patients: Conducting Phase 3 trials in Germany would allow a greater number of European patients to access PP405 within a clinical trial framework. This could potentially shorten the process to market approval in Europe and ensure faster availability of the drug once approved.
Conclusion:

Including Germany as a trial site for PP405 Phase 3 studies in 2026 would not only enhance the scientific validity of the trials but also help make this promising compound available to patients in Europe more quickly.

We therefore strongly urge you to consider our request and integrate Germany into your planning for the upcoming Phase 3 trials.

Thank you for your attention and your commitment to developing innovative treatments for hair loss.